BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24157259)

  • 21. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer.
    Straver ME; Rutgers EJ; Russell NS; Oldenburg HS; Rodenhuis S; Wesseling J; Vincent A; Peeters MT
    Eur J Cancer; 2009 Sep; 45(13):2284-92. PubMed ID: 19464164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases.
    Sakakibara M; Nagashima T; Kadowaki M; Onai Y; Fujimori T; Yokomizo J; Suzuki H; Fushimi K; Nakatani Y; Miyazaki M
    Ann Surg Oncol; 2009 Sep; 16(9):2470-8. PubMed ID: 19588201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer.
    Verdial FC; Mamtani A; Pawloski KR; Sevilimedu V; D'Alfonso TM; Zhang H; Gemignani ML; Barrio AV; Morrow M; Tadros AB
    Ann Surg Oncol; 2022 Jun; 29(6):3810-3819. PubMed ID: 35246810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
    Kai K; Arima N; Miyayama H; Yamamoto Y; Iwase H; Nishimura R
    Breast Cancer; 2009; 16(1):42-8. PubMed ID: 18504642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accurate axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer.
    Patel NA; Piper G; Patel JA; Malay MB; Julian TB
    Am Surg; 2004 Aug; 70(8):696-9; discussion 699-700. PubMed ID: 15328803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
    Steger GG; Galid A; Gnant M; Mlineritsch B; Lang A; Tausch C; Rudas M; Greil R; Wenzel C; Singer CF; Haid A; Pöstlberger S; Samonigg H; Luschin-Ebengreuth G; Kwasny W; Klug E; Kubista E; Menzel C; Jakesz R;
    J Clin Oncol; 2007 May; 25(15):2012-8. PubMed ID: 17513805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
    Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
    Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between intrinsic subtypes and tumor responses to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
    Ooe A; Takahara S; Sumiyoshi K; Yamamoto H; Kawai J; Shiba E
    Breast Dis; 2012; 34(1):9-17. PubMed ID: 23507670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer.
    Sakakibara M; Fujimori T; Miyoshi T; Nagashima T; Fujimoto H; Suzuki HT; Ohki Y; Fushimi K; Yokomizo J; Nakatani Y; Miyazaki M
    Cancer; 2012 Aug; 118(16):3899-910. PubMed ID: 22180194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
    Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
    Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?
    Daveau C; Stevens D; Brain E; Berges O; Villette S; Moisson P; Gardner M; De la Lande B; Lasry S; Labib A; Le Scodan R
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):337-42. PubMed ID: 20171795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes.
    Canavese G; Dozin B; Vecchio C; Tomei D; Villa G; Carli F; Del Mastro L; Levaggi A; Rossello C; Spinaci S; Bruzzi P; Catturich A
    Eur J Surg Oncol; 2011 Aug; 37(8):688-94. PubMed ID: 21696914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - recommendations for clinical guidance.
    Fontein DB; van de Water W; Mieog JS; Liefers GJ; van de Velde CJ
    Eur J Surg Oncol; 2013 May; 39(5):417-24. PubMed ID: 23473972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?
    Montagna G; Sevilimedu V; Fornier M; Jhaveri K; Morrow M; Pilewskie ML
    Ann Surg Oncol; 2020 Nov; 27(12):4702-4710. PubMed ID: 32839900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis.
    Park S; Park JM; Cho JH; Park HS; Kim SI; Park BW
    Ann Surg Oncol; 2013 Sep; 20(9):2858-65. PubMed ID: 23645483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological factors and nomograms predicting nonsentinel lymph node metastases after neoadjuvant chemotherapy in breast cancer patients.
    Gimbergues P; Abrial C; Durando X; Le Bouedec G; Cachin F; Penault-Llorca F; Mouret-Reynier MA; Kwiatkowski F; Maublant J; Tchirkov A; Dauplat J
    Ann Surg Oncol; 2009 Jul; 16(7):1946-51. PubMed ID: 19408057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors affecting lymph node yield in patients undergoing axillary node dissection for primary breast cancer: a single-institution review.
    Lee MC; Plews R; Rawal B; Kiluk JV; Loftus L; Laronga C
    Ann Surg Oncol; 2012 Jun; 19(6):1818-24. PubMed ID: 22203185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.